CSF1R inhibition with emactuzumab in locally advanced diff use-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study.
Emactuzumab Phase1 dTGCT
CSF1R inhibition with emactuzumab in locally advanced diff use-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study.
We are not responsible for the content. Do you want to proceed?